retatrutide cancer From Smart Drugs to Retatrutide: Medical Breakthroughs Decoded | Vantage on Firstpost Can Retatrutide Cause Cancer?

Discover how GLP-1 receptor agonists affect lipid profiles, who may benefit from modest cholesterol improvements, and how these medications compare with statins and other lipid-lowering treatments in UK clinical practice.

are overweight or have obesity

While telehealth can increase patient access to medications, it is critical to ensure that prescribing practices adhere to accepted standards outlined in clinical practice guidelines

GLP-1 medications like semaglutide (Ozempic, Wegovy) are everywhere right now.But for all the headlines, very few conversations actually explain what these

CMS has announced a new, time-limited program called the Medicare GLP-1 Bridge

Recent Findings Retatrutide is the first triple agonist (acting on GLP-1/GIP/glucagon receptors) with published phase 2 data in people with obesity as well as in people with T2D